Some new and amended listings are being added to the Pharmaceutical Benefits Scheme (PBS).
Description of the measure
Some new and amended listings are being added to the Pharmaceutical Benefits Scheme (PBS). These changes give eligible Australians and overseas visitors more affordable access to vital medicines.
The new listings are:
- incobotulinum toxin A – new listing from 1 April 2015, for 3 indications:
- cervical dystonia (spasmodic torticollis)
- blepharospasm or hemifacial spasm
- spasticity of the upper limb following a stroke
- alemtuzumab – new listing from 1 April 2015, for the treatment of patients with relapsing-remitting multiple sclerosis
- cetuximab – new listing from 1 June 2015, for the first-line treatment of metastatic colorectal cancer
The amended listings are:
- capecitabine – amended listing from 1 March 2015, to unrestricted (previously Authority Required)
- certolizumab pegol – amended listing from 1 April 2015, for the treatment of patients with psoriatic arthritis
- dapagliflozin – amended listing from 1 April 2015, as an add-on therapy to insulin to treat diabetes mellitus type 2
- rituximab – amended listing from 1 April 2015, for the treatment of non-Hodgkin’s lymphoma
- adalimumab – amended listing to include the treatment of severe refractory Crohn’s disease in paediatric patients aged 6 to 17 years
- omalizumab – amended listing from 1 May 2015, for the treatment of adult and adolescent patients with uncontrolled severe allergic asthma
- leuprorelin – amended listing from 1 April 2015 to include the treatment of effective suppression of puberty
- antineoplastic and immunomodulating agents - amended listing from 1 May 2015, agents available on the Section 85 – General schedule from Authority Required or Authority (streamlined) to Restricted/Unrestricted Benefit; or Authority Required to Authority (streamlined)
Questions and answers
Who is affected by this measure
Australians and eligible overseas visitors who receive PBS medicines. Health professionals including pharmacists, general practitioners, specialists and nurse practitioners will also be affected.
Who is eligible for this measure
The Schedule of Pharmaceutical Benefits has been updated to show the new and amended listings. Health professionals will decide if their patient is eligible under the restriction criteria listed in the Schedule of Pharmaceutical Benefits.
The date this measure will start and finish
The new and amended listings will be added on:
- 1 March 2015: capecitabine
- 1 April 2015: incobotulinum toxin A, certolizumab pegol, alemtuzumab, dapagliflozin, leuprorelin and rituximab
- 1 May 2015: omalizumab, antineoplastic and immunomodulating agents
- 1 June 2015: cetuximab
This measure is ongoing.